A xenograft and cell line model of SDH-deficient pheochromocytoma derived from Sdhb+/− rats
Loading...
Download
Associated Records
Authors
File Licence
Editors
Date
2020-06-01
Source Title
Endocrine-Related Cancer
Journal Title
Journal ISSN
Volume Title
Publisher
BIOSCIENTIFICA LTD
Melbourne Authors
Affiliation
Clinical Pathology
Document Type
Journal Article
Subject Code
Citation
Powers, J. F., Cochran, B., Baleja, J. D., Sikes, H. D., Pattison, A. D., Zhang, X., Lomakin, I., Shepard-Barry, A., Pacak, K., Moon, S. J., Langford, T. F., Stein, K. T., Tothill, R. W., Ouyang, Y. & Tischler, A. S. (2020). A xenograft and cell line model of SDH-deficient pheochromocytoma derived from Sdhb+/− rats. Endocrine Related Cancer, 27 (6), pp.337-354. https://doi.org/10.1530/ERC-19-0474.
Access Status
Open Access
Access URL
Open Access URL
Open Access at PMC
Linked Resource URL
NHMRC Grant Code
ARC Grant Code
Description
Abstract
Tumors caused by loss-of-function mutations in genes encoding TCA cycle enzymes have been recently discovered and are now of great interest. Mutations in succinate dehydrogenase (SDH) subunits cause pheochromocytoma/paraganglioma (PCPG) and syndromically associated tumors, which differ phenotypically and clinically from more common SDH-intact tumors of the same types. Consequences of SDH deficiency include rewired metabolism, pseudohypoxic signaling and altered redox balance. PCPG with SDHB mutations are particularly aggressive, and development of treatments has been hampered by lack of valid experimental models. Attempts to develop mouse models have been unsuccessful. Using a new strategy, we developed a xenograft and cell line model of SDH-deficient pheochromocytoma from rats with a heterozygous germline Sdhb mutation. The genome, transcriptome and metabolome of this model, called RS0, closely resemble those of SDHB-mutated human PCPGs, making it the most valid model now available. Strategies employed to develop RS0 may be broadly applicable to other SDH-deficient tumors.